Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

Figure 2 Odds/probabilities of obtaining a sustained virological response with regard to interleukin 28B-genotype and different therapy regimen. The differences between the shown estimates correspond to the odds ratios. A greater difference of odds between the both IL-28B-genotype corresponds to a more beneficial effect. SVR: Sustained virological response; IL-28B: Interleukin 28B.